{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:39:55Z","timestamp":1762004395517},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.jcv.2012.05.012","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T19:46:00Z","timestamp":1340221560000},"page":"58-61","source":"Crossref","is-referenced-by-count":11,"title":["Different impact of IL28B polymorphisms on response to peginterferon-\u03b1 plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b"],"prefix":"10.1016","volume":"55","author":[{"given":"Eugenia","family":"Vispo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma I.","family":"Rallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Labarga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Miguel","family":"Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2012.05.012_bib0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"55","author":"EASL","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2012.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2012.05.012_bib0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2012.05.012_bib0020","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/656811","article-title":"Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV","volume":"51","author":"Medrano","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2012.05.012_bib0025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordard","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2012.05.012_bib0030","unstructured":"Poordard F, Bronowicki JP, Gordon S, Zeuzem S, Jacobson I, Sulkowski M, et al. Factors that predict response of patients with HCV infection to boceprevir. Gastroenterology, in press."},{"key":"10.1016\/j.jcv.2012.05.012_bib0035","series-title":"61st American Association for the Study of Liver Diseases (AASLD)","article-title":"Telaprevir combination with peginterferon and ribavirin in genotype 1 HCV treatment-na\u00efve patients: final results of phase 3 ADVANCE study","author":"Jacobson","year":"2010"},{"key":"10.1016\/j.jcv.2012.05.012_bib0040","doi-asserted-by":"crossref","unstructured":"Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz E, Horban A, et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial or null responder patients treated with telaprevir\/peginterferon\/ribavirin: retrospective analysis of the REALIZE study. In: Abstracts of the 46th EASL annual meeting. Berlin, Germany; 2011 [Abstract 13]. J Hepatol 2011;54(Suppl. 1):6\u20137.","DOI":"10.1016\/S0168-8278(11)60015-9"},{"key":"10.1016\/j.jcv.2012.05.012_bib0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2012.05.012_bib0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2012.05.012_bib0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.jcv.2012.05.012_bib0060","first-page":"1026","article-title":"Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in treatment-na\u00efve genotype 1A, 1B and 3 HCV-infected patients","volume":"50","author":"Brainard","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2012.05.012_bib0065","doi-asserted-by":"crossref","unstructured":"McPhee F, Hernandez D, Yu F, Friborg J, Levine S, Chen C, et al. Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. In: Abstracts of the 46th EASL annual meeting. Berlin, Germany; 2011 [Abstract 63]. J Hepatol 2011;54(Suppl. 1):28\u20139.","DOI":"10.1016\/S0168-8278(11)60065-2"},{"key":"10.1016\/j.jcv.2012.05.012_bib0070","doi-asserted-by":"crossref","unstructured":"Lenz O, Fevery B, Vijgen L, Berg T, Tanwandee T, Thongsawat S, et al. TMC-435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon\/ribavirin treatment: virological analyses of the ASPIRE trial. In: 47th EASL. Barcelona, April 18\u201322; 2012 [Abstract 9]. J Hepatol 2012;56(Suppl. 1):5.","DOI":"10.1016\/S0168-8278(12)60023-3"},{"key":"10.1016\/j.jcv.2012.05.012_bib0075","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV\u2013HIV international panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2012.05.012_bib0080","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2012.05.012_bib0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2012.05.012_bib0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2012.05.012_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.qai.0000194238.15831.c7","article-title":"Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV\/hepatitis C virus-coinfected patients","volume":"41","author":"de Ledinghen","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2012.05.012_bib0100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/597350","article-title":"Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV\u2013hepatitis C virus coinfection","volume":"48","author":"Kirk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2012.05.012_bib0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","article-title":"Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay","volume":"14","author":"Livak","year":"1999","journal-title":"Genet Anal"},{"key":"10.1016\/j.jcv.2012.05.012_bib0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","article-title":"Hepatitis C virus uptake and changes in the prevalence of HCV genotypes in HIV\/HCV-coinfected patients","volume":"18","author":"Medrano","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jcv.2012.05.012_bib0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2334-11-124","article-title":"Core mutations, IL28B polymorphisms and response to peginterferon\/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection","volume":"11","author":"Alestig","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jcv.2012.05.012_bib0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jmv.23207","article-title":"Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated interferon-alpha 2b and ribavirin","volume":"84","author":"Hayashi","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcv.2012.05.012_bib0125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2012.05.012_bib0130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2012.05.012_bib0135","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcv.2012.05.012_bib0140","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.01598-08","article-title":"GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796","volume":"53","author":"McCown","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcv.2012.05.012_bib0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)","volume":"65","author":"Kieffer","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcv.2012.05.012_bib0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for hepatitis C virus infection","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2012.05.012_bib0155","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMe1100829","article-title":"A new era of hepatitis C therapy begins","volume":"364","author":"Jensen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2012.05.012_bib0160","doi-asserted-by":"crossref","unstructured":"Soriano C. A new era for hepatitis C \u2013 diagnostic tools and new weapons. ACS Chem Biochem; in press.","DOI":"10.1021\/ml300098k"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653212002053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653212002053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T16:56:23Z","timestamp":1542905783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653212002053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1386653212002053"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2012.05.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}